BACKGROUND: The Outpatient Bleeding Risk Index (BRI) prospectively classified patients who were at high, intermediate, or low risk for warfarin-related major bleeding. However, there are only 2 published validation studies of the index and neither included veterans. OBJECTIVE: To determine the accuracy of the BRI in patients attending a Veterans Affairs (VA) anticoagulation clinic and to specifically evaluate the accuracy of the BRI in patients with atrial fibrillation. DESIGN: Retrospective cohort study. PATIENTS AND MEASUREMENTS: Using the BRI, all patients managed by the Anticoagulation Clinic between January 1, 2001 and December 31, 2002 were classified as high, intermediate, or low risk for major bleeding. Bleeds were identified via quality-assurance reports. Poisson regression was used to determine whether there was an association between the index and the development of bleeding. RESULTS: The rate of major bleeding was 10.6%, 2.5%, and 0.8% per patient-year of warfarin in the high-, intermediate-, and low-risk groups, respectively. Patients in the high-risk category had 14 times the rate of major bleeding of those in the low-risk group (incidence rate ratio (IRR) 14; 95% confidence interval (CI), 1.9 to 104.7). The rate of major bleeding was significantly different between the high- and intermediate-risk categories (P<.001). Among those with atrial fibrillation, patients in the high-risk category had 6 times the major bleeding rate of those in the intermediate- and low-risk groups combined (IRR=6; 95% CI, 2.4 to 15.3). CONCLUSIONS: The BRI discriminates between high- and intermediate-risk patients in a VA anticoagulation clinic, including those with atrial fibrillation.
BACKGROUND: The OutpatientBleeding Risk Index (BRI) prospectively classified patients who were at high, intermediate, or low risk for warfarin-related major bleeding. However, there are only 2 published validation studies of the index and neither included veterans. OBJECTIVE: To determine the accuracy of the BRI in patients attending a Veterans Affairs (VA) anticoagulation clinic and to specifically evaluate the accuracy of the BRI in patients with atrial fibrillation. DESIGN: Retrospective cohort study. PATIENTS AND MEASUREMENTS: Using the BRI, all patients managed by the Anticoagulation Clinic between January 1, 2001 and December 31, 2002 were classified as high, intermediate, or low risk for major bleeding. Bleeds were identified via quality-assurance reports. Poisson regression was used to determine whether there was an association between the index and the development of bleeding. RESULTS: The rate of major bleeding was 10.6%, 2.5%, and 0.8% per patient-year of warfarin in the high-, intermediate-, and low-risk groups, respectively. Patients in the high-risk category had 14 times the rate of major bleeding of those in the low-risk group (incidence rate ratio (IRR) 14; 95% confidence interval (CI), 1.9 to 104.7). The rate of major bleeding was significantly different between the high- and intermediate-risk categories (P<.001). Among those with atrial fibrillation, patients in the high-risk category had 6 times the major bleeding rate of those in the intermediate- and low-risk groups combined (IRR=6; 95% CI, 2.4 to 15.3). CONCLUSIONS: The BRI discriminates between high- and intermediate-risk patients in a VA anticoagulation clinic, including those with atrial fibrillation.
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Philip S Wells; Melissa A Forgie; Maureen Simms; Alison Greene; Donna Touchie; Geoffrey Lewis; Jodi Anderson; Marc A Rodger Journal: Arch Intern Med Date: 2003-04-28
Authors: Robert G Hart; Jonathan L Halperin; Lesly A Pearce; David C Anderson; Richard A Kronmal; Ruth McBride; Elaine Nasco; David G Sherman; Robert L Talbert; John R Marler Journal: Ann Intern Med Date: 2003-05-20 Impact factor: 25.391
Authors: Regina E Roller; Bernhard Iglseder; Peter Dovjak; Monika Lechleitner; Ulrike Sommeregger; Ursula Benvenuti-Falger; Ronald Otto; Birgit Böhmdorfer; Markus Gosch Journal: Wien Med Wochenschr Date: 2010-06
Authors: Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Siqin Ye; Bin Cheng; Gregory Y H Lip; Richard Buchsbaum; Ralph L Sacco; Bruce Levin; Marco R Di Tullio; Min Qian; Douglas L Mann; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; J P Mohr; Susan Graham; Arthur J Labovitz; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; John L P Thompson; Shunichi Homma Journal: Am J Cardiol Date: 2015-06-24 Impact factor: 2.778
Authors: Isa I Valentín; Giselle Rivera; Mariely Nieves-Plaza; Iadelisse Cruz; Jessica Y Renta; Carmen L Cadilla; Juan F Feliu; Richard L Seip; Gualberto Ruaño; Jorge Duconge Journal: P R Health Sci J Date: 2014-09 Impact factor: 0.705
Authors: Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders Journal: Thromb Haemost Date: 2018-10-30 Impact factor: 6.681